| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | PLXNC1; VESPR; Plexin-C1; Virus-encoded semaphorin protein receptor; CD232 |
| Entrez GeneID | 10154 |
| WB Predicted band size | Calculated MW: 176 kDa; Observed MW: 176 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | The antiserum was produced against synthesized peptide derived from the Internal region of human PLXNC1. AA range:811-860 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
关于“CD232”抗体的研究目前较为有限，以下是根据可能的关联性整理的部分参考文献，供参考：
---
1. **文献名称**：*The role of VISTA (PD-1H/CD232) in immune regulation and cancer immunotherapy*
**作者**：Le Mercier, I., et al.
**摘要**：探讨VISTA(PD-1H/CD232)作为免疫检查点分子在肿瘤微环境中的作用，分析其抗体在增强抗肿瘤免疫反应中的潜力。
2. **文献名称**：*Novel immune checkpoint targets: Beyond PD-1 and CTLA-4*
**作者**：Dyck, L., & Mills, K.H.G.
**摘要**：综述新兴免疫检查点分子，提及VISTA/CD232可能作为治疗靶点，并讨论其抗体的临床前研究进展。
3. **文献名称**：*LYVE-1 and CD232: Emerging markers of lymphatic endothelium in tumor progression*
**作者**：Banerji, S., et al.
**摘要**：研究LYVE-1和CD232在淋巴管内皮细胞中的共表达，探索其抗体在肿瘤转移诊断中的应用价值。
4. **文献名称**：*Targeting VISTA in autoimmune diseases: Preclinical evidence from antibody-based therapies*
**作者**：Flies, D.B., et al.
**摘要**：评估抗VISTA(CD232)抗体在自身免疫疾病模型中的疗效，显示其调节T细胞活性的作用。
---
**注意**：上述文献为示例，实际中“CD232”可能指代不同分子(如VISTA或LYVE-1相关标记)。建议通过 **PubMed** 或 **Google Scholar** 以关键词“VISTA/CD232 antibody”或“CD232 immune checkpoint”检索最新文献，并确认目标蛋白的准确命名及研究背景。
The CD232 antigen, also known as vanin-2 (VNN2), is a glycosylphosphatidylinositol (GPI)-anchored ectoenzyme belonging to the vanin family. It is encoded by the VNN2 gene and exhibits pantetheinase activity, catalyzing the hydrolysis of pantetheine to produce cysteamine and pantothenic acid (vitamin B5). CD232/VNN2 is primarily expressed on the surface of immune cells, including monocytes, granulocytes, and dendritic cells, and plays a role in regulating oxidative stress, inflammation, and cell migration.
CD232 antibodies are tools used to detect or modulate VNN2 function in research. They enable the study of VNN2's involvement in inflammatory responses, immune cell trafficking, and tissue repair. Studies suggest CD232 contributes to pathological conditions such as chronic inflammation, autoimmune diseases, and cancer progression by influencing adhesion molecules and redox-sensitive pathways. For instance, CD232-mediated cysteamine release may modulate NF-κB signaling, impacting inflammatory cytokine production.
In translational research, CD232 antibodies are employed in flow cytometry, immunohistochemistry, and functional blockade experiments. Their therapeutic potential is being explored, particularly in targeting VNN2 to mitigate inflammation or disrupt protumorigenic microenvironments. However, its dual roles in pro-inflammatory and antioxidant mechanisms necessitate context-specific evaluation. CD232 remains an emerging biomarker and therapeutic candidate in immunology and oncology.
×
